Picture of Ion Beam Applications SA logo

IBAB — Ion Beam Applications SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Belgium's IBA FY 2025 sales beat expectations on proton therapy growth

Overview

Belgium particle accelerator tech firm's FY 2025 sales rose 24%, beating analyst expectations

Adjusted EBIT for FY 2025 increased 58% yr/yr, driven by strong Proton Therapy contribution

Company launched share buyback program post period end for up to 400,000 shares

Outlook

IBA sets FY 2026 group adjusted EBIT guidance of at least €32 mln

Company reaffirms its mid-term outlook

Company expects working capital improvement to accelerate from 2027

Result Drivers

PROTON THERAPY GROWTH - Strong execution and commercial momentum in Proton Therapy drove 44% net sales growth and a significant positive contribution to Adjusted EBIT

ORDER INTAKE & BACKLOG - Record equipment order intake and all-time high backlog provided significant revenue visibility

EQUIPMENT PROFITABILITY MIX - Gross margin declined to 32.2% due to less favorable equipment profitability mix, including legacy low-margin Proton Therapy projects, partially offset by productivity improvements

Company press release: ID:nGNE2CZN1H

Key Details

MetricBeat/MissActualConsensus Estimate
FY SalesBeatEUR 620.20 mlnEUR 597.08 mln (4 Analysts)
FY Net IncomeEUR 12.70 mln
FY Gross Margin32.20%
FY Pretax ProfitEUR 18.80 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Ion Beam Applications SA

See all news